Editors and Contributors

Editors

Rolf A. Stahel Comprehensive Cancer Center Zürich, Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland
Solange Peters Department of Oncology, University of Lausanne, Lausanne, Switzerland
Marina Chiara Garassino Medical Oncology Unit at Fondazione IRCSS “Istituto Nazionale dei Tumori”, Milan, Italy

Contributors

Chapter 1. Epidemiology, pathogenesis and risk factors

E Capelletto Department of Oncology, University of Turin, Turin, Italy
S Novello Department of Oncology, University of Turin, Turin, Italy

Chapter 2. Prevention and screening of lung cancer

G Veronesi Robotic Thoracic Surgery, Humanitas Research Hospital, Milan, Italy

Chapter 3. Diagnosing lung cancer

C Dooms Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium

Chapter 4. Histopathological and molecular characterisation of lung cancer

A Warth Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

Chapter 5. Principles of surgery of non-small cell lung cancer

MA Hoda Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria
T Klikovits Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria
W Klepetko Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria

Chapter 6. Principles of radiotherapy of thoracic tumours

T Finazzi Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands
S Senan Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands

Chapter 7. Adjuvant and neoadjuvant therapy

B Besse Gustave Roussy Cancer Campus, Villejuif; Paris-Sud University, Orsay, France

Chapter 8. Treatment of metastatic non-small cell lung cancer

N Reinmuth Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting, Germany
M Reck Department of Thoracic Oncology, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany

Chapter 9. Treatment of small cell lung cancer: chemotherapy and radiotherapy

D De Ruysscher MAASTRO Clinic, GROW Research Institute, Maastricht University, Maastricht, Netherlands

Chapter 10. Targeted therapy for oncogene-addicted metastatic non-small cell lung cancer

M-J Ahn Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
JF Gainor Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Chapter 11. Immunotherapy for thoracic malignancies: Part A - Non-small cell lung cancer

KHJ Lim Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
V Calvo Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain
M Provencio Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain
R Califano Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Department of Medical Oncology, Manchester University Hospital NHS Foundation Trust, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK

Chapter 12. Malignant pleural mesothelioma

GL Ceresoli Thoracic and GU Oncology Unit, Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy
L Gianoncelli Thoracic and GU Oncology Unit, Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy; Supported by Fondazione Buzzi Unicem, Casale Monferrato (AL), Italy
M Bonomi Thoracic and GU Oncology Unit, Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy

Chapter 13. Thymic malignancies

N Girard Thorax Institute Curie Montsouris, Curie Institute, Paris, France
C Merveilleux du Vignaux Cancer Institute of the Hospices Civils de Lyon, Lyon, France

Chapter 14. Neuroendocrine tumours of lung origin

MC Garassino Medical Oncology Unit at Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
D Femia Medical Oncology Unit at Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
S Pusceddu Medical Oncology Unit at Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Chapter 15. Immunotherapy for thoracic malignancies: Part B - Small cell lung cancer and mesothelioma

V Calvo Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain
KHJ Lim Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
R Califano Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Department of Medical Oncology, Manchester University Hospital NHS Foundation Trust, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK
M Provencio Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain

Chapter 16. Emerging targets and new agents in lung cancer

A Januszewski Department of Medicine, Royal Marsden Hospital, London, UK
SB Popat Department of Medicine, Royal Marsden Hospital, London, UK

Declarations of Interest 

S Peters: Receipt of honoraria or consultation fees: AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda; gave talks in a company-organised public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Takeda; receipt of grants/research support: (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, Pfizer.

RA Stahel: Honoraria as a consultant at advisory boards from: AbbVie, AstraZeneca, Boehringer Ingelheim, MSD, Pfizer, Roche, Takeda; honoraria as a speaker from: AstraZeneca, Boehringer Ingelheim, MSD, Roche; data monitoring committee: Roche and Takeda; financial support of ETOP trials (President and Scientific Chair): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech, MSD, Roche, Pfizer.

Chapter 1. Epidemiology, pathogenesis and risk factors

E Capelletto: Advisory boards and consultant activities for Boehringer Ingelheim and AstraZeneca.
S Novello: Speaker bureau for Eli Lilly, MSD, Roche, Bristol-Myers Squibb.

Chapter 2. Prevention and screening of lung cancer

G Veronesi: Honoraria from AB Medica SpA, Medtronic, Verb Medica.

Chapter 3. Diagnosing lung cancer

C Dooms: No conflict of interest.

Chapter 4. Histopathological and molecular characterisation of lung cancer

A Warth: No conflict of interest.

Chapter 5. Principles of surgery of non-small cell lung cancer

MA Hoda: No conflict of interest.
T Klikovits: No conflict of interest.
W Klepetko: No conflict of interest.

Chapter 6. Principles of radiotherapy of thoracic tumours

T Finazzi: Advisory board: AstraZeneca.
S Senan: Departmental research grants: Varian Medical Systems, ViewRay Inc., AstraZeneca; advisory boards: AstraZeneca, Celgene, Varian Medical Systems, MSD.

Chapter 7. Adjuvant and neoadjuvant therapy

B Besse: Sponsored research at Gustave Roussy Cancer Center, AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma.

Chapter 8. Treatment of metastatic non-small cell lung cancer

N Reinmuth: Personal fees (speakers and consulting honoraria): Bristol-Myers Squibb, F. Hoffmann-La Roche, Lilly, Novartis, Boehringer Ingelheim, AstraZeneca, Amgen, Pfizer, MSD.
M Reck: Honoraria for lectures and consultancy: Lilly, Roche, AstraZeneca, MSD, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Novartis, Pfizer.

Chapter 9. Treatment of small cell lung cancer: chemotherapy and radiotherapy

D De Ruysscher: Advisory board for Bristol-Myers Squibb, Merck Serono, Merck/Pfizer, Celgene, Roche/Genentech, AstraZeneca; industry-funded research for Bristol-Myers Squibb and AstraZeneca.

Chapter 10. Targeted therapy for oncogene-addicted metastatic non-small cell lung cancer

M-J Ahn: Compensated consultant for AstraZeneca, Boehringer Ingelheim, Lilly, Bristol-Myers Squibb, ONO, Merck, MSD, Novartis, Takeda, Alpha Pharmaceuticals.
JF Gainor: Compensated consultant or received honoraria from Bristol-Myers Squibb, Pfizer, Regeneron, Oncorus, Genentech, Ariad/Takeda, Loxo, Jounce, Agios, Amgen, Incyte, Theravance, Novartis, Merck, Clovis.

Chapter 11. Immunotherapy for thoracic malignancies: Part A - Non-small cell lung cancer

KHJ Lim: No conflict of interest.
V Calvo: No conflict of interest.
M Provencio: Honoraria for consultancy work from MSD, Bristol-Myers Squibb, Roche, Medimmune/AstraZeneca.
R Califano: Honoraria for consultancy work from MSD, Bristol-Myers Squibb, Roche, Medimmune/AstraZeneca.

Chapter 12. Malignant pleural mesothelioma

GL Ceresoli: Advisory fees: Boehringer Ingelheim, Ipsen, Pfizer; travel expenses: Novocure.
L Gianoncelli: Supported by Fondazione Buzzi Unicem, Casale Monferrato (AL), Italy; no conflict of interest.
M Bonomi: No conflict of interest.

Chapter 13. Thymic malignancies

N Girard: Compensated consultancy and honoraria for lectures for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Lilly, MSD, Pfizer.
C Merveilleux du Vignaux: No conflict of interest.

Chapter 14. Neuroendocrine tumours of lung origin

MC Garassino: Honoraria for speaker, advisory role from: Eli Lilly, Boehringer Ingelheim, Otsuka, Bristol-Myers Squibb, Celgene, Dephaforum Srl, Takeda; advisory role: Novartis, Pfizer, Inivata; speaker, advisory role, Steering Committee: MSD, AstraZeneca; speaker: ACCMED, Forum Service Srl, Medscape, McCann Healthcare, S.O.S. Srl, Crems Srl, Incyte. Institutional financial support for clinical trials (local PI, enrollment in clinical trials): Bristol-Myers Squibb, Roche, Tiziana Life Sciences, Clovis, Merck Serono, AstraZeneca, Celgene, Otsuka, Bayer, Pfizer, MSD, Eli Lilly, Novartis, Incyte, AstraZeneca, GlaxoSmithKline S.p.A., Takeda.
D Femia: No conflict of interest.
S Pusceddu: No conflict of interest.

Chapter 15. Immunotherapy for thoracic malignancies: Part B - Small cell lung cancer and mesothelioma

V Calvo: No conflict of interest.
KHJ Lim: No conflict of interest.
R Califano: Honoraria for consultancy work from MSD, Bristol-Myers Squibb, Roche, Medimmune/AstraZeneca.
M Provencio: Honoraria for consultancy work from MSD, Bristol-Myers Squibb, Roche, Medimmune/AstraZeneca.

Chapter 16. Emerging targets and new agents in lung cancer

A Januszewski: No conflict of interest.
SB Popat: Compensated consultant to AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Guardant Health, MSD, Novartis, Pfizer, Roche, Takeda.

« Previous Page Next Page »

Last update: 12 June 2019